These 3 Stocks Trounced the S&P 500 in the First Half of 2026 -- and Wall Street Thinks 1 of Them Could Soar Even More

Three biotech companies—Moderna, Revolution Medicines, and Axsome Therapeutics—significantly outperformed the S&P 500 in the first half of 2026 with double- and triple-digit gains. While Moderna faces expected pullback despite flu vaccine approval prospects, and Revolution Medicines shows modest upside, Wall Street expects Axsome to climb another 13% due to recent drug approvals and strong pipeline progress.